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The emergence and spread of antibiotic-resistant Gram-negative bacteria (rGNB) across global healthcare networks
presents a significant threat to public health. As the number of effective antibiotics available to treat these resistant
organisms dwindles, it is essential that we devisemore effective strategies for controlling their proliferation. Recently,
whole-genome sequencing has emerged as a disruptive technology that has transformed our understanding of the
evolution and epidemiology of diverse rGNB species, and it has the potential to guide strategies for controlling the
evolution and spread of resistance. Here, we review specific areas in which genomics has already made a significant
impact, including outbreak investigations, regional epidemiology, clinical diagnostics, resistance evolution, and the
study of epidemic lineages. While highlighting early successes, we also point to the next steps needed to translate this
technology into strategies to improve public health and clinical medicine.
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Introduction
In recent years, multidrug-resistant organisms
(MDROs) that are refractory to nearly all avail-
able treatments have emerged and spread globally.1,2
The inability of drug discovery pipelines to keep up
with the pace at which resistance has neutralized
existing antibiotics has created an imminent global
public health crisis.3,4 The threat of MDROs is par-
ticularly dire within our healthcare systems, where
more than one in 25 hospitalized patients have a
healthcare-associated infection on any given day.5
Hospitalized patients have comorbidities that make
themmore susceptible to contracting infections and
less equipped to combat these infectionswithout the
aid of antibiotics. Thus, increases in antibiotic resis-
tance among healthcare-associated pathogens have
directly led to increases in morbidity and mortal-
ity among affected patients.6–8 Recently, the evolu-
tion of antibiotic resistance has reached a crucial
tipping point with the emergence of pan-resistant
[Correction added on April 5, 2018, after first online pub-
lication: Author affiliations were corrected.]
organisms that have caused infections untreatable
with any available antibiotic.2,9–11 In the absence of
novel treatments to combat these resistant infec-
tions, there is an urgent need for the development
of more effective strategies to control the spread of
MDROs and prevent patients from acquiring infec-
tions that are increasingly difficult to treat.
Over the past several decades, healthcare epi-
demiologists have made significant strides in track-
ing the spread of infections within and between
healthcare facilities by supplementing traditional
gumshoe epidemiology with a diverse suite of
molecular typing tools.12 Molecular typingmethods
probe the structure (e.g., pulsed-field gel elec-
trophoresis (PFGE)) or sequence (e.g., multilo-
cus sequence typing (MLST)) of microbial genetic
material in order to quantify the relationships
among infectious isolates and gauge whether they
are plausibly linked by transmission.12–14 While
much has been learned about the local and global
epidemiology of MDROs using molecular typing
approaches, all classical techniques are associated
with major limitations. First, methods based on
doi: 10.1111/nyas.13672
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genome structure present difficulties in interpre-
tation, because these molecular types (e.g., pul-
sotype) do not evolve at a consistent rate.14 The
lack of a quantifiable relationship between variation
in molecular type and historical relatedness forces
investigators to apply arbitrary cutoffs in evaluat-
ing whether two isolates could be epidemiologically
linked.13 A second issue with classical methods is
that there is no single method that performs well at
all time scales. For instance, MLST has been shown
to be extremely powerful in characterizing regional
or global pathogen populations but lacks the res-
olution to discern transmission patterns within
a healthcare institution.15 Conversely, PFGE pro-
vides resolution sufficient to discern between closely
related strains but is often too dynamic to compare
pathogen populations in different regions.15 Finally,
an important limitation of all classical molecular
typing approaches is that they provide no insight
into how genetic changes relate to phenotypic dif-
ferences among strains.
Recently, whole-genome sequencing (WGS) has
entered the forefront of molecular epidemiology,
providing a one-size-fits-all tool that overcomes vir-
tually all of the limitations of prior methods. First,
WGS has been shown to provide sufficient reso-
lution to elucidate transmission pathways within a
single institution, while at the same time yielding
data that facilitate the placement of global pathogen
populations in the context of one another.16–18 Sec-
ond, by probing every base pair in the genome,
WGS allows investigators to translate genetic dif-
ferences into historical relationships among isolates
by exploiting the molecular clock at which muta-
tions accumulate over time.19,20 Having a molec-
ular type that can be related to a molecular clock
has allowed investigators to explicitly test whether
two strains are linked on epidemiologically relevant
time scales while avoiding the need to set arbitrary
cutoffs.21 Finally, by interrogating variation across
the entire genome, investigators can leverage pheno-
typic information from decades of biochemical and
genetic experiments to generate hypotheses regard-
ing the phenotypic impact of observed genomic
variation.22–24
Early work applying WGS to study MDROs has
demonstrated the disruptive nature of this tech-
nology and led to fundamental insights into the
evolution and epidemiology of the most significant
healthcare-associated pathogens. Here, we high-
light recent applications of WGS to characterize the
emergence and spread of Gram-negative MDROs
across global healthcare systems. While WGS has
had an equally significant impact on Gram-positive
MDROs, we focus on Gram-negatives to highlight
some of the unique features of this increasingly
burdensome class of healthcare pathogens.25,26 For
each application ofWGS, we also explore challenges
and opportunities in maximizing the translational
impact of this transformative technology in the
realms of clinical practice and public health.
Hospital epidemiology and outbreak
investigation
Among the earliest applications ofWGS to study the
epidemiology ofMDROs was to elucidate transmis-
sion networks during hospital outbreaks.16,17,27,28
Outbreak investigations are initiated when there is a
spike in infections with anMDRO species. A typical
investigation consists of case finding, where inves-
tigators look for additional patients who might be
involved in an outbreak, as well as contact tracing,
where investigators look for common exposures or
contact between patients, with the goal of iden-
tifying contaminated infrastructure or pathways
of patient-to-patient transmission. Traditional epi-
demiological investigations are often supplemented
with molecular typing in order to narrow the focus
to groups of patients that are thought to be part of a
transmission chain, based upon their harboring of a
relatedMDRO strain. However, this combination of
contact tracing and low-resolution molecular typ-
ing has been complicated by the emergence of epi-
demic MDRO lineages that have become endemic
in regional healthcare institutions. In particular, the
endemicity of these epidemic lineages is such that
it is not uncommon for multiple patients to enter a
healthcare institution already colonized or infected
with a common strain. Thus, grouping together all
patients harboring a common strain will result in
patients being grouped together who are not nec-
essarily connected by transmission within a health-
care institution. The inability to accurately group
patients linked by transmission can make it diffi-
cult to identify contaminated infrastructure or other
potentially modifiable factors that are mediating
transmission.
Several studies have reported the successful
application of WGS to partition patients into
transmission clusters when other molecular typing
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approaches failed. Our first application of WGS
to study a hospital outbreak was for an outbreak
of multidrug-resistant (MDR) Acinetobacter
baumannii.28 Although our hospital had not had
a previous outbreak with MDR A. baumannii,
PFGE typing of outbreak isolates indicated that
we had three different strain types simultaneously
circulating in the hospital. We therefore wondered
if this outbreak was due to three contemporaneous
introductions into the hospital or if the circulating
strain of A. baumannii had evolved in such a way
that its PFGE type changed during the course of the
outbreak. Application of WGS to representatives of
the three outbreak strains led us to the conclusion
that two importation events had seeded this
outbreak. Two outbreak strains were traced back to
an importation event by a single patient, with the
variation in strain type believed to be due to large
recombination events across the genome. The third
outbreak strain was traced back to a non-MDRO
strain that had been circulating in the hospital
months earlier, and in the intervening time had
picked up several drug-resistance determinants.
In a separate study, Willems and colleagues were
able to partition an A. baumannii outbreak into
two clusters and show that transmission was
largely confined within specific hospital wards,
thereby focusing infection control interventions.29
Kanamori and colleagues were similarly able to
partition an A. baumannii outbreak into clusters
due to independent importation events and,
similar to our investigation, found that filtering out
recombinant regions of the genome was critical to
make accurate epidemiological inferences.30
The success of WGS in dissecting healthcare out-
breaks is not limited to A. baumannii. Stoesser and
colleagues appliedWGS to isolates fromanoutbreak
of MDR Enterobacter cloacae that primarily affected
neonates.31 This analysis revealed two separate clus-
ters that were again largely confined to individual
units. In addition, one of the clusters matched an
isolate retrieved from a soap dispenser, implicat-
ing this contaminant as the point source seeding
this cluster. Several groups have also applied WGS
to study outbreaks of carbapenem-resistant Kleb-
siella pneumoniae and other MDR Gram-negatives,
many of which observed multiple strain importa-
tions, followed by the preferential transmission of
particular strain types.30–33 Upon partitioning mul-
tistrain outbreaks into clusters, these studies found
that most transmission events could be accounted
for by spatiotemporal overlap between patients in
the facility, again emphasizing the importance of
defining transmission clusters to facilitate insights
into transmission pathways. Importantly, most of
the aforementioned studies found that the incorpo-
ration of WGS data into the outbreak investigation
facilitated insights into the origins of circulating
strains and pathways of nosocomial transmission
that would have been inaccessible with lower reso-
lution typing methods (e.g., MLST and PFGE).
In addition to grouping patients into transmis-
sion clusters, several studies have been able to
use WGS to elucidate extremely nuanced insights
into the propagation of outbreaks with different
MDROs. Asmentioned above,multiple groups have
reported that time and space overlap on hospital
wards can explain the majority of transmissions for
organisms such as K. pneumoniae and E. cloacae,
which are thought to primarily spread patient-to-
patient via healthcare worker contamination.34,35
However, for more environmentally hearty organ-
isms like A. baumannii and Pseudomonas aerugi-
nosa, WGS has allowed for causal links to be made
between environmental contamination and ongo-
ing transmission. In studying a prolonged outbreak
of A. baumannii, Halachev and colleagues were able
to use WGS to link contamination in an operating
theater to transmission between patients who other-
wise had no overlap in the hospital.33 Several groups
have linked Pseudomonas isolates from sink drains
to isolates taken from patients.36,37 While direction-
ality was not clear inmany of these cases, one report
found that genetically identical isolates persisted in
a sink trap months after the linked patient had been
in the room, demonstrating at the very least that
infection-causing isolates can persist in the hospital
environment for extended periods of time.36
Finally, WGS has also yielded nontrivial insights
into the structure of transmission networks. Apply-
ing WGS to an outbreak of carbapenem-resistant
K. pneumoniae allowed us to demonstrate the role
of asymptomatic carriers inoutbreakpropagation.17
In particular, we observed that, despite a 3-week
gap in infections following discharge of the index
patient, there had in fact been multiple transmis-
sions from this index patient that seeded an out-
break that affected 18 patients. This observation led
to the implementation of more rigorous surveil-
lance culturing,whichwas critical in identifying and
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isolating all asymptomatically colonized patients
and stopping the outbreak. In applying WGS to an
outbreak of P. aeruginosa,Willmann and colleagues
found evidence for the disproportionate role of a
few super-spreaders in propagating the outbreak
strain.36 Future insights such as these into the struc-
ture of transmission networks for different MDROs
will be critical in identifying and properlymanaging
high-risk patients.
While these early studies show how powerful
WGS is for outbreak investigations, there are still
important challenges that need to be considered.
First, several groups, including ours, have reported
how intrapatient genetic heterogeneity of coloniz-
ing and contaminating populations can confound
accurate descriptions of transmission networks.17,21
The impact of this is still not fully appreciated, but
the potential for many MDRO species to colonize
hosts for months or years raises the possibility that
certain patients may harbor extremely diverse col-
onizing populations.38–42 Moreover, the potential
for multiple acquisitions in high-transmission set-
tings has been documented and can also confound
transmission inference.43–45 While there are both
analytical and sequencing-based strategies to deal
with these issues, they result in decreased power
and increased cost, respectively.46–48 One solution to
combat decreased power of genetic inferences is to
supplement transmission- inference pipelines with
comprehensive location or contact-tracing data.49
A second solution is to apply methods that account
for potential intrahost diversity anduncertainty sur-
rounding the potential transmission, events when
constructing transmission networks.46,47
Another challenge in standardizingWGS for clin-
ical applications is agreement in the field regarding
best practices and common analytical frameworks.
Likely, the optimal framework will depend on
the question at hand, where computationally
friendly pipelines like whole-genome multi-locus
sequence typing (WG-MLST) might be preferable
for real-time analyses, while more sophisticated
phylogenetic approaches that take full advantage
of genomic data can be applied in retrospective
analyses.46,47,50,51 A related issue is coming to a
consensus as to whether the establishment of
concrete variant thresholds is appropriate for
evaluating whether two patients are plausibly
linked by transmission.16,19,49,52 Owing to the
aforementioned issue of increased variation due to
prolonged asymptomatic colonization of patients,
it is unlikely that a hard variant cutoff that is not
overly conservative will work in all situations.53,54
We believe that a more viable solution for distin-
guishing between transmission and importation
is enacting more comprehensive sequencing of
regional isolate collections, such that isolates from
within a facility can be placed into a broader
regional context.55,56 Finally, one must consider
whether there is benefit to having WGS embedded
in clinical microbiology laboratories for real-time
investigation or whether retrospective investiga-
tions by healthcare researchers and public health
laboratories are sufficient.57 To answer this question
will require well-conceived and designed studies
that quantify the benefits of real-time sequencing.58
Regional epidemiology at different
geographic scales
While the applicationofWGS tounderstand intrafa-
cility transmission has the potential to reduce infec-
tion rates by stemming nosocomial transmission,
it is increasingly appreciated that the connectivity
of healthcare networks will ultimately necessitate
a regional approach to infection control.59 Such a
regional approach will require understanding the
structure and dynamics of pathogen populations
at different temporal and geographic scales. As the
cost of sequencing has decreased and allowed for the
application ofWGS to large strain collections, it has
become clear that a genomics approach can yield
unparalleled insights into pathogen populations at
local, regional, and global scales.
In addition to targeted sequencing of suspected
outbreaks, WGS has been applied more broadly
at single institutions to discern local pathogen
population structure and gauge the relative impacts
of importation and transmission within health-
care facilities. To try and understand an observed
increase in carbapenem-resistant Enterobacteriaceae
(CRE) at their institution, Pecora and colleagues
sequenced all CRE infection isolates over a 3-year
period.60 Genomic comparison revealed that there
was little transmission and that incidence of CRE at
this institution was primarily driven by the sporadic
importation of organisms harboring diverse mobile
resistance elements. Mellmann and colleagues took
this to the next level by sequencing all methicillin-
resistant Staphylococcus aureus, vancomycin-
resistant enterococci, and resistant Gram-negative
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bacteria (rGNB) at their institution to discern the
relative impact of transmission and importation.58
Their genomic investigation revealed that there
was little transmission of rGNB, which led to
modification of infection-control procedures to
more effectively allocate resources. Importantly,
the authors then applied WGS to validate that their
procedural modifications did not have negative
consequences on transmission rates. In the ultimate
display of sequencing power, Roach and colleagues
indiscriminately sequenced every clinical isolate
taken from ICU patients over the course of a year.43
Analysis of 1229genomes from391patients revealed
an unexpected level of species and strain diversity
in the hospital and painted a picture of overall low
transmission rates, with a handful of successful
lineages being observed in multiple patients.
While sequencing isolate collections from single
institutions provides insights into what is happen-
ing within the confines of a facility, understanding
the ultimate origin of MDROs circulating within
hospitals will require sequencing and analysis of
regional isolate collections. Moradigaravand and
colleagues recently took such a regional approach to
understand the population structure of three MDR
members of the Enterobacteriaceae family: E. cloa-
cae, Serratia marcescens, and K. pneumoniae.56,61,62
In contrast to MDR K. pneumoniae, in which epi-
demic clones dominate specific regions, E. cloacae
and S. marcescens both exhibited a polyclonal struc-
ture across 37 hospitals in the UK and Ireland,
indicating the convergent emergence and spread
of multiple MDR lineages. This finding contrasts
to a recent report by Hargreaves and colleagues,
who observed the emergence and spread of a lin-
eage of bla-KPC–carrying E. cloacae across mul-
tiple hospitals in North Dakota and Minnesota.63
Thus, polyclonal population structures are not nec-
essarily a static feature of a given MDRO species,
with the acquisition of a key resistance determi-
nant potentially leading to the emergence of clonal
epidemic lineages.64–66 The emergence of epidemic
clones from a background of polyclonality has also
been reported in multiple studies applying WGS to
regional sets of P. aeruginosa isolates from cystic
fibrosis (CF) patients. While it had been doctrine
that infections in CF patients are due to acquisition
of environmental strains, Dettman and colleagues
applied WGS to demonstrate the existence of com-
mon strain infecting CF patients in multiple hos-
pitals in North America and the UK.67 Work by
this same group and others went on to show that
this epidemic lineage had acquired genetic variants
beneficial in the CF lung environment and spread
globally.68
Two recent genomic epidemiological analyses
of regional Neisseria gonorrhoeae were among the
first to move beyond the description of popula-
tion structures to identify epidemiological drivers
of transmission.69,70 By integrating robust epidemi-
ological data on timing of infections, sexual prefer-
ence, and past contacts into phylogenetic analyses,
these studies were able to demonstrate local geo-
graphic clustering of strains circulating among indi-
viduals with common sexual preference. Of note,
the study by De Silva et al., which focused on cases
from the city of Brightonover a 4-year period, found
that local transmission networks in Brighton were
supplemented by outside importations from both
geographic disparate parts of the UK as well as the
United States.69 Thus, by casting an increasingly
wider net, the authors were able to determine the
relative impact of transmission and importation at
different levels of geographic granularity.
These and other genomic epidemiology studies
have begun to inform our understanding of the
pathways by which MDRO lineages have spread
at local and global scales. However, these prior
studies have largely been descriptive, in the sense
that the clinical and epidemiological factors that
affect regional MDRO prevalence and drive the
spread of MDROs across healthcare institutions
remain largely hidden. For MDROs that primarily
spread within healthcare settings, it is likely that
patient movement between healthcare facilities
drives regional spread. Through the integration of
genomic and patient-transfer data, we were able
to demonstrate that a handful of patient-transfer
events were sufficient to explain a regional outbreak
of carbapenem-resistant K. pneumoniae that
affected 40 patients and 26 healthcare facilities in
four adjacent counties in Indiana and Illinois.55
Moving forward, it will be important to expand on
this proof-of-principle study, overlaying additional
metadata on clinical practices and resident patient
populations, such that we can understand what
drives variation in the prevalence of different
MDRO species across healthcare settings, even
over short geographic distances. Finally, full
understanding of MDRO spread will require
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more comprehensive sampling. This will require
consideration of not only clinical isolates, but also
isolates gathered through active surveillance cul-
turing of asymptomatic individuals across facilities
comprising connected healthcare networks.
Evolution and dissemination of clonal
lineages
A recurring theme from both genomic and clas-
sical molecular epidemiological studies of various
MDR Gram-negative organisms is the observation
of epidemic lineages that have emerged and spread
globally since the dawn of the antibiotic era.71,72 The
proliferation of these lineages has prompted many
investigators to search for common characteristics
that might account for their success, but thus far
the only characteristic that unifies these epidemic
clones is their resistance to one or more common
antimicrobials.72 While antibiotic resistance is by
definition necessary for a clone to become epidemic,
it does not appear in itself sufficient, as there are
numerous examples of less prominent clones hav-
ing the same resistance determinants as their epi-
demic counterparts.64,73,74 Far from being simply an
academic exercise, understanding why certain lin-
eages explode on the global scene is critical formore
effectivemonitoringandearlydetectionof emergent
lineagesofhighepidemicpotential. By applying evo-
lutionary genomics approaches, investigators have
begun to chart the evolutionary trajectories of epi-
demic lineages, which is an essential first step in
understanding whether the success of these clones
is due to chance accumulation of beneficial muta-
tions or if the genetic background of these ancestral
strains predisposed them to thrive in the antibiotic
era. Several of these lineages have been reviewed in
detail elsewhere, and we therefore provide only a
brief discussion of this area.66,67,72,73
As alluded to above, antibiotic resistance is a com-
mon feature of epidemic clones that have emerged
in the antibiotic era. However, the critical resis-
tance determinants and the mode by which they
were acquired vary among MDRO lineages. ST131
is a globally disseminated clone of Escherichia
coli that is associated with both community- and
healthcare-acquired infections.75 ST131 stands out
among other E. coli lineages because of its common
association with fluoroquinolone and -lactam
resistance, mediated by target site mutations
and a plasmid-associated extended-spectrum
-lactamase, respectively.72,75 Recent comparative
genomics studies have revealed a nested sub-
structure to the ST131 lineage, wherein there
was a sequential acquisition of fluoroquinolone
resistance–conferring mutations, followed by a bla-
CTX-M-15–containing plasmid.75,76 Further work
has unearthed additional complexity, in that
bla-CTX-M-15 seems to be found on multiple
plasmids, which vary in their cargo, indicating
that there may have been multiple plasmid-
acquisition events.75 A second lineage defined by
a resistance plasmid is bla-KPC–carrying ST258
K. pneumoniae. While ST258 can be resistant to
nearly all antibiotics, its global proliferation appears
to have coincidedwith the acquisition of a bla-KPC–
carrying plasmid.65,77 Similar to ST131, bla-KPC
has been observed in multiple plasmid contexts
within ST258.78 It is noteworthy that, while the
plasmid backbones vary, both bla-CTX-M-15 and
bla-KPC are typically carried on narrow host range
IncF plasmids, suggesting that these plasmids may
harbor characteristics that either minimize the cost
of plasmidmaintenance or encode for other features
that are beneficial to epidemic clones.79
In contrast to the ST131 and ST258 lineages that
are defined by the acquisition of particular resis-
tance elements, the European epidemic clones I
and II (ECI and ECII) of A. baumannii appear
to be defined more by the breadth and flexibil-
ity of their resistome.75,80,81 While ECI and ECII
strains carry resistance plasmids, the defining fea-
tures of these strains are massive chromosomally
encoded resistance islands that contain multiple
antibiotic-resistance determinants that are associ-
ated with mobile genetic elements.82–84 These resis-
tance islands have proved to be extremely dynamic,
with many different configurations reported.85 In
addition to horizontally acquired elements, A. bau-
mannii also has several intrinsic resistance genes,
including -lactamases and efflux pumps, which
can become activated under antibiotic pressure by
mobilization of Insertion Sequence (IS) elements
that carry strong promoters.83,86 Similar to A. bau-
mannii, resistance in MDR epidemic clones ST235
and ST111 of P. aeruginosa is also attributable to
a combination of intrinsic resistance elements and
chromosomally associated mobile elements.87
While most attention has been given to acqui-
sition of antibiotic-resistance determinants, sev-
eral MDRO epidemic lineages have also acquired
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foreign genetic material with the potential to con-
fer advantages beyond survival under antibiotic
pressure. Recent comparative genomic studies of
K. pneumoniae ST258 found that among the few
defining events in the emergence of this lineage
were two large recombination events that resulted
in altered capsular biosynthetic loci.65,78 It has
been hypothesized that these capsular switching
events are important for immune evasion and per-
sistence in hosts. Recombination events altering
antigenic molecules have also been observed in
E. coli and A. baumannii, with recombinant switch-
ing of lipopolysaccharide (LPS) loci reported in
both species.28,88,89 In addition to altering putative
antigenic determinants, horizontal transfer events
have also been observed that have the potential
to modify interactions with the host environment
in other ways. Studies in ST131 and ST258 have
both found horizontal transfer events affecting fim-
briae andpili, whichmay provide advantages in host
colonization.65,90,91
Despite large comparative genomic studies
charting the evolutionary trajectories of prominent
Gram-negative lineages, it still remains unclearwhat
has made these epidemic clones so successful. One
fundamental question is whether the acquisition
of key resistant determinants was the critical event
that propelled these lineages or if instead it was the
genetic background of the ancestors of epidemic
clones that primed them for success. To begin to
address this question will require a better under-
standing of capabilities of these organisms outside
of their resistance. For example, studies that assess
alternate explanations for success, such as environ-
mental heartiness, capacity for efficient colonization
of the host, and the ability to outcompete resident
microbiota, are needed to identify factors that
underlie the success of these lineages.92 A second
issue hindering our understanding of the emergence
of epidemic lineages is a potential observation
bias, wherein the dissemination and evolution of
resistant organisms is preferentially monitored
comparedwith their susceptible counterparts.More
comprehensive surveillance sampling of organisms
regardless of resistance or virulence phenotypes
would enable generation of amore complete picture
of the global population structure of prevalent
pathogens with epidemic lineages and facilitate the
retracing of temporal events leading up to the emer-
gence of new dominant resistant lineages. Another
formof observation bias is the preferential sampling
of individuals in healthcare settings, despite the
existence of both resistant and susceptible strains
of MDRO species circulating in the community.
This makes it unclear whether these strains were
previously spreading effectively outside hospitals
or if the prevalence of these lineages exploded due
to acquisition of resistance and selection in the
high-antibiotic environment of healthcare facilities.
Once we begin to understand the basis for success
of dominant resistant lineages, we may be able to
recognize and predict the emergence of resistant
organisms, with the goal of intervening before they
negatively affect public health.
Evolution of antibiotic resistance
While epidemic lineages are of special interest
due to their prevalence and tendency toward
multidrug resistance, the evolution and spread of
antibiotic resistance in less-prolific Gram-negative
lineages is also of major concern for several reasons.
First, increased resistance is expected overall to
be associated with worse patient outcomes due
to increased time to optimal therapy.93 Second,
resistance determinants in low-risk clones can
become mobilized and be transferred to other
MDRO lineages and other species.94,95 Finally,
as discussed above, it is unclear if and when
the acquisition of a resistant determinant in a
low-risk clone could set it on a trajectory toward
becoming a significant regional or global threat. In
recent years, bacterial genomics has been applied
to track the real-time evolution of resistance
within patients, to elucidate genetic mechanisms
underlying resistance in different MDROs, and to
characterize the relationship between antibiotic
resistance determinants found in different human
and environmental reservoirs.96–99 It is hoped that
these insights into the evolution and ecology of
antibiotic resistance can motivate the conception
and implementation of more effective strategies for
impeding the proliferation of resistance.
Mutational modes of resistance
The most straightforward experimental design for
studying clinical resistance evolution is the appli-
cation of WGS to longitudinal isolates taken from
patients in which resistance has evolved during the
course of treatment. In these situations, it is pre-
sumed that, if resistance has emerged during a short
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treatment course, it is likely due to a small num-
ber of high-impact mutations.98 Indeed, studies
employing this approach to study resistance evo-
lution typically only observe a handful of muta-
tions between intrapatient pairs, which facilitates
the identification of causal variants by identify-
ing genes or pathways mutated in multiple patient
time courses.97 A drug for which several groups
have studied intrapatient resistance evolution is col-
istin. Colistin is a last-line drug for treating MDR
Gram-negatives that are resistant to carbapenem
antibiotics.100,101 The prospect of widespread col-
istin resistance is of great concern, as there are
limited treatment options beyond colistin for the
treatment of infections caused by carbapenemase-
producing Gram-negatives, such as K. pneumo-
niae and A. baumannii.102 Interestingly, in both
K. pneumoniae and A. baumannii, genomic
sequencing studies have found mutations in a com-
mon regulatory pathway controlling LPS modifica-
tion systems, indicating that LPSmodification is key
to resistance in both species.103–105 This genome-
derived hypothesis that altered LPS modification
underlies resistance was ultimately confirmed for
both organisms by comparing LPSmodifications in
susceptible and resistant isolates.103,106
An important caveat in studying resistance
evolution in individual patients is that the larger
epidemiological significance of observed resistance
mutations or mechanisms cannot necessarily be
inferred. This disconnect between short-term and
long-term impacts of resistance evolution is due to
fitness costs associated with resistance that might
limit the ultimate viability of resistant mutants once
the selective pressure of the drug is removed.107 In
other words, resistance alleles that emerge within
patients might not be sufficiently fit to effectively
spread to other patients. To understand the fate
of colistin-resistant mutants in A. baumannii,
we collected additional patient isolates following
withdrawal of colistin treatment and found that the
fitness cost associated with resistance was so severe
that, soon after colistin was withdrawn, susceptible
isolates re-emerged and outcompeted resistant
isolates within individual patients.28 However, in
one patient, we ultimately identified a low-cost
resistance mutant that emerged and was sufficiently
fit to be detected following termination of colistin
treatment. We then went on to show that this
mutant was transmitted to other patients, thereby
providing additional evidence for its relative fitness
and its potential to be a resistance mutant with
epidemic potential.
Another important consideration in studying
resistance evolution in patients is that there can
be multiple resistance alleles present in infecting
populations, which will be missed if WGS is
performed on only a few clones.21 Moreover, it may
not always be obvious from which colonizing or
infecting population within the patient resistance
emerged. For example, many MDROs initially
colonize the gastrointestinal (GI) tract before
migrating and causing infections at other sites,
such as the lungs or blood.108,109 If a patient has
sequential susceptible and resistant isolates taken
from their lung, it could be that resistant isolates
actually emerged in the GI tract and migrated back
to the lung. This distinction may ultimately be
extremely important in understanding the popula-
tion dynamics underlying resistance evolution and
gaining a better understanding of the probability of
resistance emergence during treatment.
Horizontal transfer and acquisition of
resistance
In contrast to the large number of studies doc-
umenting mutational resistance emergence in
patients, there have been fewer reports document-
ing horizontal gene transfer (HGT) underlying
resistance emergence during treatment. The diffi-
culty in studying HGT derives from the fact that
these are presumed to be rare events, and because
it can be difficult to demonstrate that the transfer
event occurred in a patient, even when the putative
source and donor strains are isolated. Despite
these challenges, anecdotal reports have begun
to emerge documenting the transfer of resistance
within the context of individual patients.110,111
Through a combination of experimental and
clinical evidence, Sidjabat et al. demonstrated
that, in a single patient, the KPC gene was likely
transferred from an infecting K. pneumoniae to
E. coli via recombination of plasmid sequences
and then subsequently transferred to S. marcescens
via conjugation.110 Hardiman et al. attempted to
understand drivers of resistance transfer in patients
by measuring in vitro KPC transfer rates with
different plasmid backgrounds and environmental
conditions.112 However, in this study, in vitro
conjugation rates did not correlate with presumed
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in vivo rates of plasmid mobilization in patients
during an outbreak, highlighting the need for
future studies that determine factors associated
with horizontal transfer during patient treatment.
The observation that the transfer of resistance ele-
ments between different MDRO strains and species
may not be as uncommon as once thought has
led investigators to attempt to track the spread of
resistance proliferation in the context of hospital
outbreaks.113,114 For example, the outbreak investi-
gatedbyMathers et al. revealed that theprevalenceof
CRE at this institution was due to a highly complex
plasmid transfer network, where intergenus trans-
fer of a promiscuous KPC plasmid, transposition of
KPC onto different plasmid backbones, and circula-
tion of diverse KPC+ lineages all manifested during
the CRE outbreak. Similarly, Conlan et al. identified
both shared and distinct carbapenemase-carrying
plasmids in several Enterobacteriacae species at their
institution. Adding to this complexity, the authors
found that, while in some cases intrapatient hor-
izontal transfer of resistance elements was likely,
in other cases patients harbored multiple species
with common resistance elements where HGT was
clearly not the origin. Both studies highlight the
complex pathways by which mobile resistance ele-
ments spread and the importance of not onlymoni-
toring prevalence of resistance but also tracking the
mobile genetic elements capable of disseminating
resistance in healthcare settings.
In addition to resistance transfer betweenMDRO
species within patients, it is thought that other
reservoirs within and outside hospitals may be hubs
for resistance dissemination.115,116 One potential
reservoir of resistance markers outside of health-
care settings is hospital effluent. Several groups
have used metagenomics approaches to detect
resistance markers and mobile genetic elements
in hospital wastewater.117–121 Growing evidence
that environmental water organisms can take
up clinically important resistance markers when
exposed to these wastewaters further bolsters this
hypothesis.121 Recently, Rowe et al.used a combined
metagenomic/metatranscriptomic approach to
measure resistance gene abundance and expression,
as well as antibiotic concentrations in effluents
from different sites that varied in antibiotic use.119
In support of hospital practices playing a role in
promoting the environmental resistome, they found
that catchment water from hospitals was enriched
for-lactamases compared with other sites and that
hospital effluent -lactamase levels correlated with
hospital antibiotic usage over time.119 Water sources
within the hospital have also been implicated as
a location where resistance transfer could occur.
Recent work investigating the role of sinks, drains,
and other hospital waterways ismotivated by several
reports of outbreaks where resistant organisms
have been isolated from these sites.122
The debate over the relative contributions of dif-
ferent reservoirs to resistance dissemination within
hospitals recently came to a head in the case of
mcr-1, which confers transferrable colistin resis-
tance. Since its initial observation on an inter-
species plasmid in 2015, mcr-1 has been identified
in the human gutmicrobiome, wastewater, commu-
nity, and animal sources.123–127 This identification
of a previously unknown mobile resistance element
in all previously mentioned hypothesized reservoirs
demonstrates formcr-1 what is likely true for other
resistance mechanisms: that the transfer and dis-
semination of mobile resistance is likely due to a
complex chain of events that take place acrossmulti-
ple ecological settings.Much of the controversy over
which reservoirs are the most important for breed-
ing resistance in healthcare settings stems from the
fact that the definitive studies examining relative
contributions of hypothesized reservoirs of resis-
tance for prevalent pathogens have yet to be carried
out. The reservoir is likely different for different
pathogens, given that the natural histories of various
resistant organisms (e.g., environmental heartiness
and colonization niche) differ significantly. Further
complicating the elucidation of the role of hypoth-
esized resistance reservoirs is that the detection of a
resistance marker in a particular location does not
inform the timing or direction of resistance transfer
from one putative reservoir to another.
Though it is clear that horizontal transfer of
resistance is important to the epidemiology of resis-
tant Gram-negatives, there are several fundamental
unanswered questions regarding the mechanism
and pathways of resistance transfer. For example,
though there is extensive in vitroworkexamining the
fitness effects of mutations contributing to antibi-
otic resistance, thefitness costs of carryingparticular
resistance elements or mutations in the context
of hypothesized real-world reservoirs and patient
carriage or infection are unknown.107 Studies that
examine the evolution of organisms within their
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real-world context (e.g., longitudinal sampling of
colonized patients and evolution on colonized hos-
pital surfaces) are needed to address these questions.
Furthermore, little is known about where resistance
initially emerges andwhat clinical and environmen-
tal risk factors drive emergence. For example, while
multiple studies have assessed the impact of targeted
infection preventatives aimed at decolonization of
patients or water reservoirs independently, studies
that measure the relative contribution of multiple
reservoirs, as well as the cost-effectiveness and
efficacy of different decontamination strategies on
patient outcomes, are needed.128–131 Finally, while
it is known that particular patients with specific
characteristics are more prone to developing resis-
tant infections, it has yet to be assessed how the risk
of having resistance emerge through mutation or
transfer during the context of particular antibiotic
treatments is distributed among patients. So far,
studies of resistance evolution in patients have
been predominantly anecdotal, and therefore there
is little insight into why resistance emerges in
particular patients and not in others.
Clinical diagnostics
A central objective of the clinical microbiology lab-
oratory is to gather information about the causative
organism of an infection in order to guide opti-
mal therapy.132,133 Rapid organism identification
is critically important, as delays in the initia-
tion of appropriate treatment are associated with
poor patient outcomes. This urgent need has led
to the deployment of technologies and workflows
aimed at reducing turnaround times between sam-
ple collection, organism identification, and suscep-
tibility testing.26,134,135 Newer rapid-identification
methods, such as matrix-assisted laser desorp-
tion/ionization time-of-flight (MALDI-ToF), have
drastically reduced turnaround time in clinical
microbiology laboratories and led to improvements
in empiric antibiotic prescribing practices.136–138
However, while these rapid-identification methods
have yielded some gains, they are often limited
in their speed by the need to first culture speci-
mens and limited in their utility by only providing
species-level classifications. Strain-level discrimina-
tion is not only vital information for infection con-
trol teams in their efforts to determine if an out-
break is occurring, but could also be utilized in
guiding treatment decisions, as certain lineages have
the strong associationswith resistance and virulence
phenotypes.139–143 Despite our incomplete under-
standing of the genetic mechanisms of virulence
and resistance for prominent pathogens, genome-
guidedmethods hold great promise as rapid clinical
diagnostics with the potential to reduce turnaround
times for organism identification and susceptibility
testing, aswell as aid infection-prevention investiga-
tions, by providing the ultimate resolution for deter-
mining relatedness of strains in healthcare settings.
Reliance on microbial culture hinders rapid
organism identification because culture can take
days, or in some cases weeks, for some resistant
organisms.57,144 For this reason, much attention has
shifted to development of culture-free diagnostics,
which have the ability to identify the causative
agent of infections and outbreaks of unknown
etiology.145–148 For example, a recent study applied
metagenomic sequencing directly to prosthetic
joint infection samples and demonstrated that this
technique can be used to accurately diagnose this
type of infection.149 The application of genomics
directly to patient samples is particularly attractive
for prosthetic joint infections, as the organisms that
cause these infections can be present at very low
levels and take 1–2 weeks to grow, whereas genomic
pipelines can detect organisms and identify clini-
cally relevant phenotypes within hours.150–153 The
management of another slow-growing organism
for which resistance is a concern, Mycobacterium
tuberculosis, is another clinical situation that might
be improved with rapid genomic diagnostics.
Votintseva et al. recently showed highly accurate
identification and susceptibility profiling of clinical
M. tuberculosis samples in 12 h, whereas culture-
dependent phenotypic methods for M. tuberculosis
susceptibility profiling can take weeks tomonths.153
The outcomes of critically ill patients depend
on how fast they can start appropriate antibiotic
therapy; however, typical turnaround times for
susceptibility testing in clinical microbiology
laboratories for even non-slow-growing organisms
range from 2 to 3 days to weeks, which may be
detrimentally long in certain cases.57,154 Further
illustrating the potential for rapid turnaround,
Leggett et al. recently demonstrated real-time
organism and resistance profile identification from
the feces of an ill infant that took less than 1 hour.152
Before an organism has been identified in a
clinical diagnostic laboratory, patients with severe
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infections (e.g., bloodstream infections) are often
treated empirically, and they are then switched to an
antibiotic with known efficacy once a pathogen and
its susceptibilities are determined.155 In addition to
organism identification, genomic methods have the
potential to decrease time-to-appropriate-therapy
initiation by identifying resistance markers and
virulence factors. Culture-free susceptibility iden-
tification methods are particularly attractive, as the
antibiotic susceptibility of the infecting organism
is also major barrier to the rapid initiation of
appropriate and successful treatment.26,57,93,156,157
There are now several platforms that can be used to
predict resistance phenotypes fromWGSdata.158,159
In addition to susceptibilities, information from the
genomic detection of virulence determinants could
aid in the identification of high-risk strains, provid-
ing insight into the probable disease they may cause
or their transmissibility in hospital settings.160,161
For example, the epidemic lineage KPC+
K. pneumoniae ST258 shows variation in its
virulence depending on the KPC allele it carries
and is hypothesized to be more virulent because
of genetic changes in its capsule locus.162 Rapid
identification of organisms belonging to hyper-
virulent or highly transmissible clones could alert
healthcare practitioners to place these patients
into appropriate infection control precautions and
rapidly initiate effective therapy.
In addition to the application of genomic diag-
nostics to guide patient treatment, there is interest
in the use of genomics in clinical laboratories
for surveillance and outbreak detection. Several
genomically informed rapid-typing methods have
been developed. For example, a genomically
informed approach to design multiplex PCR assays
that was recently developed has the potential to
rapidly identify causative agents in polymicrobial
infections as well as identify relatedness between
strains in outbreak settings.163,164 This application
is particularly appealing because, though it is
informed by WGS data, its use does not require
the operator to have the skill set required to
analyze genomic data, which is an additional
concern to implementing genomic diagnostics into
clinical microbiology workflows.163,165 Further-
more, genomics can be used as a gold standard
to validate or refute user-friendly typing schemes
that are commonly used. A recent study devised
a new MLST typing method for Salmonella and
validated this method against a core genome phy-
logeny to demonstrate its utility in distinguishing
strains.166
Despite advances in genomic diagnostics, there
is so far only one example in the literature of a
patient outcome being improved by genomics in
real time.167 High-risk and time-sensitive infections,
such as those in immune-compromised patients or
sepsis, could benefit immensely from this technol-
ogy, but moving real-time genomic diagnostics into
clinics and public health laboratories will require
overcoming several additional hurdles. First, anal-
ysis platforms must be adapted for use by person-
nel in clinical microbiology laboratories. Second,
there have so far been no trials that assess whether
patient outcomes improve with implementation of
genomic approaches. An attractive application of
genomic prediction of resistance or virulence phe-
notypes is to target decolonization to patients who
are colonized, with the goal of reducing their risk for
developing and spreading infections. Currently, it is
unknown whether precision decolonization would
prove to be beneficial for patients, or if the benefit
would be outweighed by the resulting increase in
antibiotic use, which might increase the burden of
resistance and put patients at further risk for acqui-
sition of resistant pathogens.168
Recent work illustrates both the potential and
challenges of the implementation of real-time
genomic diagnostics in clinical laboratories. Shel-
burne et al. demonstrated that WGS accurately pre-
dicted resistance to extended-spectrum -lactams
in major Gram-negative pathogens, suggesting that
it may be feasible to use WGS to identify resistance
phenotypes in clinical settings.169 Still, resistance-
prediction methods are limited by their ability to
identify known markers, and existence of unknown
resistancemarkers is amajor concern for patients, as
false susceptibility identification poses a real threat
to patient outcomes. If clinical workflows are to
move toward phenotype-independent susceptibility
prediction,more effective approaches for prediction
of unknown resistance genotypes that are scalable
for real-time diagnostic workflows are needed.
When combined with future methods of improved
susceptibility prediction, a promising technology in
the realm of rapid identification and susceptibility
testing is the Oxford Nanopore platform. Already,
this platform has the capacity to generate sequence
data sufficient for species identification in under
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Table 1. Open questions in the genomic epidemiology of resistant Gram-negatives
Hospital epidemiology and outbreak
investigation
What determines the structure of transmission networks for different pathogens in
different types of healthcare settings?
What are the patient characteristics and clinical practices that affect nosocomial
transmission?
What should be the standard best practices and analytical frameworks for different
types of genomic epidemiology investigations?
What laboratory capacity for genomics should clinical microbiology, public health, or
research laboratories have for real-time epidemiological investigations?
Regional epidemiology What are the clinical and epidemiological factors that affect regional MDRO
prevalence?
What are the networks on which different MDROs spread between regional healthcare
facilities?
How can genomics be integrated into public health workflows to affect real-time
outbreak control and guide regional interventions?
Evolution and dissemination of
clonal lineages
What genomic and epidemiological factors lead to the success of epidemic lineages?
How does sampling bias affect our understanding of the genetic and epidemiological
factors underlying the emergence of epidemic lineages?
Can we predict the epidemic potential of emergent lineages and intervene to prevent
their spread?
Evolution of antibiotic resistance Can we predict the epidemiological significance of resistance that emerges within
patients?
How is resistance emergence influenced by treatment strategy and patient
characteristics?
What influences the rate of horizontal transfer of resistance to MDROs in patients?
Which potential reservoirs of antibiotic resistance are sources and which are sinks?
What is the direction of transferrable resistance flow between different reservoirs?
Clinical diagnostics Can patient outcomes be improved by implementing real-time genomic diagnostics in
clinical microbiology laboratories?
What is the capacity for genomics to reduce turnaround time for antibiotic
susceptibility testing and initiation of appropriate therapy?
How can genomics most effectively supplement phenotypic assays given limitations in
prediction of novel resistance alleles?
What is the value added of real-time genomic epidemiology investigations versus
designed retrospective studies of transmission?
an hour with computational steps performed on
standard laptop computers.152,170,171 Whether these
new technologies are best applied in everyday
diagnostic workflows or reserved for surveillance
and outbreak settings remains to be evaluated.
Though it is evident that genomic approaches have
the potential to revolutionize clinical medicine,
unlocking this potential will require key studies
that determine whether the cost of implementing
these technologies improves patient outcomes.
Conclusions
To summarize, there is an extensive and growing
body of work showing how the application of WGS
can improve our understanding of the epidemiology
and evolution of MDR Gram-negative pathogens.
We believe that the next step for moving the field
of genomic epidemiology forward is to undertake
studies integrating WGS into epidemiologic frame-
works from a study’s first conception, such that
sample collection and analysis methods can be tai-
lored to test specific epidemiologic hypotheses and
identify areas where genomics can improve health
outcomes. The design and undertaking of these
studies is not trivial and will require participa-
tion from experts across fields, including clinical
medicine, microbiology, bioinformatics, antimi-
crobial stewardship, and healthcare epidemiology.
Table 1 illustrates several fundamental questions
in healthcare epidemiology, from before genomics
were intractable, that are now within reach with
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the power of genomics and epidemiology combined
(Table 1).With continued improvement in sequenc-
ing technologies and data analysis strategies, we are
on the cusp of fulfilling the promise of genomics to
elucidate the practices that drive the emergence and
spread of antibiotic resistance, and guide interven-
tions to prevent it.
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